Biology subjects

Siklenka, K.

Publications and source records attributed to Siklenka, K..

7 recordsLinked to original sources

bioRxiv2026

Enhancer hubs govern chromatin topology and Th17 identity

Between one and two million noncoding regulatory elements have been described across mammalian genomes, but determining their functional role remains a challenge. To address this gap, we measure the regulatory potential of open chromatin regions (OCRs) in five closely related mouse CD4+ T cell subsets with ATAC-STARR-seq, then map endogenous enhancer function and three-dimensional contacts in Th17 cells with pooled CRISPR-based noncoding screens and high-resolution Micro-C. Of all CD4+ T cell OCRs, approximately 25% demonstrate largely subset-shared regulatory activity, though we identify subset-restricted active elements distinguishable by their sequence features. In Th17 cells, we reveal a set of core regulatory OCRs essential for subset polarization at the Batf, Rorc(t) and Il17a/f loci, and confirm their requirement for cell identity in vivo. At these three loci, we resolve nested yet selective enhancer-to-enhancer and enhancer-to-promoter physical interactions that converge into multi-enhancer hubs. Importantly, these hubs contain many of the strongest functional elements. Perturbation of a single enhancer within the Batf locus selectively disrupts hub contacts and Batf expression in Th17 cells, recapitulating the genome-wide transcriptional and chromatin accessibility signatures of a germline knockout. Together, this work assigns regulatory activity to accessible chromatin across CD4+ T cell subsets and couples the function of a set of essential elements to selective three-dimensional contacts in Th17 cells.

genomics↗

bioRxiv2026

Structured Pooling Improves Detection of Rare Regulatory Mutations in Population-Scale Reporter Assays

Identifying genetic variants in noncoding DNA that impact gene expression and thereby contribute to disease risk remains a difficult but important challenge in genomic medicine. Modern reporter assays such as STARR-seq and MPRA provide an efficient and effective means of testing, in very high throughput, millions of variants captured directly from patient genomes. While these assays have previously been scaled to whole genomes and, separately, to populations, we report findings from the first whole-genome population-scale STARR-seq experiment performed on 100 individuals. In order to achieve that scale we devised a novel experimental design that partitions samples into pools so as to increase allele frequencies within pools and thereby reduce expected dropout and increase signal-to-noise ratio in experimental readouts. We show that this design produces more accurate estimates of variant effect sizes, and we provide a Bayesian model for robust estimation of those effect sizes that also reports full posterior distributions for assessment of confidence in estimates. Together, these methodological innovations facilitate the detection of functional regulatory variants, particularly rare variants, with much higher accuracy and at greater scale than previously possible. We demonstrate the utility of this approach on the task of functional annotation of quantitative trait loci such as eQTLs and caQTLs, and show concordance with patterns of constraint in transcription factor binding profiles.

bioinformatics↗

bioRxiv2025

The architecture of allele-specific regulatory variant effects across five human genomes

The overwhelming majority of genetic associations with complex traits and disease involve non-coding genetic variants. Those variants are substantially enriched in gene regulatory elements, indicating that allelic impacts on gene regulatory element activity is a major contributor to those associations. As a step towards fine mapping the mechanisms within those associations, several studies have identified variants associated with gene expression and chromatin accessibility within those phenotypic associations. However, connecting those associations with functional impacts on gene regulatory element activity remains a major challenge. Here, we functionally measured allele-specific regulatory element activity across five human genomes using the genome-wide reporter assay STARR-seq. We identified tens of thousands of gene regulatory elements and estimated allele effects at [~]200,000 genetic variants therein, including [~]10,000 indels in our study population. Allelic effects on regulatory element activity correspond closely with predicted impacts on transcription factor binding motifs. The measured variant effects also allow us to fine map potential causal variants within eQTLs and chromatin QTLs from the same population. Together, these results provide an initial atlas of genome-wide variant effects across the human genome and demonstrate the potential for such approaches to prioritize causal variants for future mechanistic investigation.

genomics↗

bioRxiv2025

SMARCA2 is an essential and potent cofactor for a specific subset of the glucocorticoid response in A549 cells

Glucocorticoids are a widely used, potent class of anti-inflammatory drugs that modulate the expression of hundreds of genes across the genome. Although the glucocorticoid response is primarily carried out by the glucocorticoid receptor (NR3C1, a.k.a. GR), there are many glucocorticoid receptor co-factors that are also essential to the downstream effects. To identify novel factors necessary for the glucocorticoid gene expression response, we used a genome-wide CRISPR screen in A549 lung adenocarcinoma cells. In that screen, we knocked out every gene in the human genome, and measured the effect of expression of the glucocorticoid-induced leucine zipper (GILZ), a classic glucocorticoid-response gene. We identified two chromatin remodeling proteins, SMARCA2 and BPTF, that are essential for GILZ expression. We then evaluated the genome-wide effects of SMARCA2 and BPTF on glucocorticoid-mediated gene expression. BPTF had a highly specific role in the glucocorticoid response, affecting the expression of only a handful of genes, and having virtually no effect on dexamethasone-induced changes in chromatin accessibility. However, SMARCA2 was necessary for 27% of dexamethasone-induced transcriptional changes (152 genes), and [~]7% of dexamethasone-induced changes in chromatin accessibility (586 regions of the genome). Genomic regions with SMARCA2-dependent changes in chromatin accessibility were characterized by high dexamethasone-induced regulatory activity in a massively parallel reporter assay, and dexamethasone-induced increases in transcription factor binding and chromatin states. Taken together, these data suggest that SMARCA2 is critical for chromatin remodeling at a specific set of genomic regions with high regulatory activity, which in turn drive changes in expression for many glucocorticoid-responsive genes.

genomics↗

bioRxiv2023

Orthogonal CRISPR screens to identify transcriptional and epigenetic regulators of human CD8 T cell function

The clinical response to adoptive T cell therapies is strongly associated with transcriptional and epigenetic state. Thus, technologies to discover regulators of T cell gene networks and their corresponding phenotypes have great potential to improve the efficacy of T cell therapies. We developed pooled CRISPR screening approaches with compact epigenome editors to systematically profile the effects of activation and repression of 120 transcription factors and epigenetic modifiers on human CD8+ T cell state. These screens nominated known and novel regulators of T cell phenotypes with BATF3 emerging as a high confidence gene in both screens. We found that BATF3 overexpression promoted specific features of memory T cells such as increased IL7R expression and glycolytic capacity, while attenuating gene programs associated with cytotoxicity, regulatory T cell function, and T cell exhaustion. In the context of chronic antigen stimulation, BATF3 overexpression countered phenotypic and epigenetic signatures of T cell exhaustion. CAR T cells overexpressing BATF3 significantly outperformed control CAR T cells in both in vitro and in vivo tumor models. Moreover, we found that BATF3 programmed a transcriptional profile that correlated with positive clinical response to adoptive T cell therapy. Finally, we performed CRISPR knockout screens with and without BATF3 overexpression to define co-factors and downstream factors of BATF3, as well as other therapeutic targets. These screens pointed to a model where BATF3 interacts with JUNB and IRF4 to regulate gene expression and illuminated several other novel targets for further investigation.

genomics↗

bioRxiv2022

Multi-center integrated analysis of non-coding CRISPR screens

The ENCODE Consortiums efforts to annotate non-coding, cis-regulatory elements (CREs) have advanced our understanding of gene regulatory landscapes which play a major role in health and disease. Pooled, non-coding CRISPR screens are a promising approach for systematically investigating gene regulatory mechanisms. Here, the ENCODE Functional Characterization Centers report 109 screens comprising 346,970 individual perturbations across 13.3Mb of the genome, using a variety of methods, readouts, and statistical analyses. Across 332 functionally confirmed CRE-gene links, we identify principles for screening endogenous, non-coding elements for causal regulatory mechanisms. Nearly all CREs show strong evidence of open chromatin, and targeting accessibility peak summits is a critical component of our proposed sgRNA design rules. We provide experimental guidelines to accurately detect CREs with variable, often low, transcriptional effects. We discover a previously undescribed DNA strand-bias for CRISPRi in transcribed regions with implications for screen design and analysis. Benchmarking five screen analysis tools, we find CASA produces the most conservative CRE calls and is robust to artifacts of low-specificity sgRNAs. Together, we provide an accessible data resource, predesigned sgRNAs targeting 3,275,697 ENCODE SCREEN candidate CREs, and screening guidelines to accelerate functional characterization of the non-coding genome.

genomics↗

bioRxiv2021

Transgenic mice for in vivo epigenome editing with CRISPR-based systems

The discovery, characterization, and adaptation of the RNA-guided clustered regularly interspersed short palindromic repeat (CRISPR)-Cas9 system has greatly increased the ease with which genome and epigenome editing can be performed. Fusion of chromatin-modifying domains to the nuclease-deactivated form of Cas9 (dCas9) has enabled targeted gene activation or repression in both cultured cells and in vivo in animal models. However, delivery of the large dCas9 fusion proteins to target cell types and tissues is an obstacle to widespread adoption of these tools for in vivo studies. Here we describe the generation and validation of two conditional transgenic mouse lines for targeted gene regulation, Rosa26:LSL-dCas9-p300 for gene activation and Rosa26:LSL-dCas9-KRAB for gene repression. Using the dCas9p300 and dCas9KRAB transgenic mice we demonstrate activation or repression of genes in both the brain and liver in vivo, and T cells and fibroblasts ex vivo. We show gene regulation and targeted epigenetic modification with gRNAs targeting either transcriptional start sites (TSS) or distal enhancer elements, as well as corresponding changes to downstream phenotypes. These mouse lines are convenient and valuable tools for facile, temporally controlled, and tissue-restricted epigenome editing and manipulation of gene expression in vivo.

genomics↗